A 35.5 Billion Yuan Fujian Businessman Huang Tao Eyes Vaccine Leader Watson Biotech

Radar Finance Production Text | Written by Zhou Hui | Edited by Deep Sea

Huang Tao, a billionaire Fujian merchant with 35.5 billion yuan, may acquire his third listed company.

On the evening of March 18, leading vaccine company Watson Bio disclosed a private placement plan, announcing an intention to issue no more than 208 million A-shares to specific investors, Beijing Tengyun Xinwo Biotechnology Partnership (Limited Partnership) (hereinafter “Tengyun Xinwo”), at a price of 9.63 yuan per share, with a subscription amount not exceeding 2.003 billion yuan.

At the same time, Watson Bio stated that after the issuance, without considering other factors affecting the share capital, Tengyun Xinwo will directly hold 11.51% of the company’s shares. The shareholding ratio of Tengyun Xinwo and its concerted parties will reach 14.46% of the total shares after issuance, making Tengyun Xinwo the company’s controlling shareholder, with Huang Tao as the actual controller.

This means that after 16 years of listing, Watson Technology, with a market value of 20 billion yuan, will end its previous dispersed ownership structure and welcome its first actual controller.

Public information shows that Huang Tao was born in 1976 and is the son of well-known Fujian merchant Huang Rulun. In 1986, Huang Rulun went alone to the Philippines to seek fortune. In 1991, he returned to Fuzhou and founded the predecessor of Century Golden Source Group—Jinyuan Real Estate Co., Ltd. Subsequently, Huang Rulun invested in finance, tourism, commerce, aviation, petrochemicals, new energy, and other industries, once becoming Fujian’s richest man.

In 2018, Huang Rulun handed over the reins to Huang Tao and retreated behind the scenes, with Huang Tao officially becoming the new leader of Century Golden Source. Notably, it was also in this year that Huang Tao began to frequently act in the capital markets.

In December 2018, Huang Tao participated in Anhui Tong Technology’s private placement through Tibet Jingyuan, acquiring 13.9052 million shares, reaching a total of 19.9966 million shares by the end of that year, accounting for 4.85%. Starting March 2020, Tibet resumed increasing its holdings in Anhui Tong Technology, and by February 28, 2022, its holdings reached 81.9277 million shares, representing 19.97% of the total, making it the controlling shareholder of Anhui Tong Technology. Huang Tao also officially gained his first listed company.

It is worth noting that on the evening of March 18, Anhui Tong Technology disclosed a revised plan for a private placement of shares to specific investors for 2025, proposing to issue shares to Tibet Tengyun and Jingyuan Huizhi, raising no more than 600 million yuan to supplement the company’s working capital. After the issuance, Huang Tao, the actual controller, will hold 174 million voting rights shares, accounting for 33.93% of the company’s equity.

After gaining control of Anhui Tong Technology, Huang Tao did not stop there. In May last year, he established Shenzhen Xinchuyuan Investment Partnership (Limited Partnership) (“Xinchuyuan”). The following month, Xinchuyuan signed a “Share Transfer Agreement” and a “Voting Rights Waiver Agreement” with Cao Zhang, the controlling shareholder and actual controller of Anniel, and Wang Jianqing.

According to the agreement, Xinchuyuan will spend about 422 million yuan to acquire control of Anniel. After the change in equity, Xinchuyuan will become the controlling shareholder of Anniel, holding 27.7644 million shares, accounting for 13.03%. Huang Tao has thus gained his second listed company.

With this successful acquisition of Watson Bio, Huang Tao will welcome his third listed company. As of the close on March 20, the stock prices of Anhui Tong Technology, Anniel, and Watson Bio were 8.19 yuan, 19.17 yuan, and 12.51 yuan per share, respectively; market values were 3.509 billion yuan, 4.084 billion yuan, and 20.01 billion yuan.

Public information shows that besides directly controlling listed companies, Huang Tao also holds 6.29% of Tackle Road, 10.84% of Xinming Life Technology, 12.53% of First Service Holdings, and 9.11% of China Financial International.

According to Tianyancha, as of now, Huang Tao has held positions in 34 existing companies, including Century Golden Source Investment Group Co., Ltd., Jiujiang Zhirong Zhuoxin Investment Center (Limited Partnership), Qu Shui Juyong Business Management Co., Ltd., and Huayi Brothers (Tianjin) Real Scene Entertainment Co., Ltd.

Years of business experience have also accumulated considerable wealth for Huang Tao’s family. Hurun Research Institute previously released the “2026 Hurun Global Rich List,” showing Huang Rulun and Huang Tao’s family with a net worth of 35.5 billion yuan, ranking 871st. However, compared to 2025’s list with 36 billion yuan, their wealth decreased by 500 million yuan.